Natera Q2 Revenue Soars 38%, Gross Margin Expands, but Leverage Check Still Pending

What happened

Natera reported Q2 2026 revenue of $752.8 million, a 37.7% increase year-over-year, underscoring persistent demand for its Signatera MRD test. Gross margin rose to 64.5%, up 110 basis points, firmly within the company's guided 64%–66% range and signaling stable reimbursement dynamics. These results handily satisfy the top-line growth condition we set in our prior WAIT recommendation. However, the earnings summary lacks crucial details on operating expenses and the resulting operating loss, leaving the critical question of operating leverage unanswered. Until the full 10-Q confirms that expense growth has decelerated and losses are narrowing, the investment case for a rating upgrade remains incomplete.

Implication

Q2 revenue growth of 37.7% and gross margin of 64.5% exceed the minimum thresholds we set for a positive reassessment, indicating that Signatera demand remains robust and reimbursement is holding firm. However, the preliminary release omits operating expense details, which were a major concern in Q1 when R&D and SG&A grew faster than revenue. Without evidence that operating losses are narrowing in tandem with revenue expansion, the stock remains a WAIT; the market may continue to penalize persistent losses despite strong top-line growth. Investors should examine the full 10-Q for opex trends and oncology unit growth to determine whether the operating leverage thesis is strengthening or if cost pressures persist.

Thesis delta

Q2 results reinforce the top-line growth story and show margin stability, but the absence of opex data keeps the operating leverage thesis unresolved. No change to the WAIT rating until cost discipline is demonstrated.